Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - TENAX THERAPEUTICS, INC. | tenx_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): March 14,
2018
Tenax Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-34600
|
|
26-2593535
|
(State
or other jurisdiction of incorporation)
|
|
(CommissionFile
Number)
|
|
(IRS
EmployerIdentification No.)
|
ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address
of principal executive offices) (Zip Code)
919-855-2100
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01
Other
Events.
On
March 14, 2018, Tenax
Therapeutics, Inc. (the “Company”) issued a press
release announcing that on March 12, 2018, the Company received a
letter from the Nasdaq Listing Qualifications Department
(“Nasdaq”) notifying the
Company that the minimum bid price of its common stock was at least
$1.00 for ten (10) consecutive business days. Accordingly, the
Company has regained compliance with the Nasdaq minimum bid price
requirement and the matter is now closed.
A copy
of the press release issued by the Company with respect to this
matter is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Item
9.01
Financial
Statements and Exhibits.
(d)
Exhibits
Exhibit No.
|
|
Description
|
|
|
|
|
Press
Release dated March 14,
2018
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Tenax Therapeutics, Inc. |
|
|
|
|
|
|
Date:
March 14, 2018
|
By:
|
/s/
Michael
B. Jebsen
|
|
|
|
Michael
B. Jebsen
|
|
|
|
Chief
Financial Officer and Interim Chief Executive
Officer
|
|